General Information
|
|
Product
|
AGE Peptide
|
Description
|
Antigenic Blocking Peptide Advance Glycated Endproduct Antibody
|
Verified Applications
|
Immunodepletion, Immunocompetition
|
Peptide Description
|
Purified glycated ribonuclease corresponding to AGE. Glycated ribonuclease (RNase) prepared by incubating RNase with glucose at 37⁰C for several months.
|
Physical Properties
|
|
Quantity
|
250 µg
|
Volume
|
100 µl
|
Form
|
Antigenic Blocking Peptide
|
Storage
|
-20⁰C for long term storage
|
Application Protocol
|
Competition/Depletion assay
|
Refer to competition assay protocol
|
Protein
|
Overview
|
Mediates interactions of advanced glycosylation end products (AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators.
|
Molecular Function
|
Inflammatory Response
|
Subcellular Location
|
Isoform 1 : Cell membrane; Single-pass type I membrane protein
Isoform 2 : Secreted
Isoform 10 : Cell membrane 1 Publication; Single-pass type I membrane protein
|
Expression
|
Endothelial cells.
|
Structure
|
Interacts with S100A1 and APP (By similarity). Interacts with S100B, S100A12 and S100A14. Constitutive homodimer; disulfide-linked.
|
Alternative Nomenclature
|
Advanced glycation end products antibody
AGEs antibody
|
|
|